Clinical trial
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in…
NCT00111696 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00111696 |
|---|---|
| Title | Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma |
| Official title | Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Advanced Malignant Melanoma |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Biological |
| Interventions | MEDI-522 |
| Enrollment | 18 |
| Start date | May 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | May 25, 2005 |
| Last update posted | Mar 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: